- The Significance of MicroRNA Let-7b, miR-30c, and miR-200c Expression in Breast Cancers.
-
Sung Min Chun, Hee Jung Park, Chul Hwan Kim, Insun Kim
-
Korean J Pathol. 2011;45(4):354-360.
-
DOI: https://doi.org/10.4132/KoreanJPathol.2011.45.4.354
-
-
3,687
View
-
49
Download
-
2
Crossref
-
 Abstract
 PDF
- BACKGROUND
MicroRNA (miRNA) is a class of noncoding protein RNA as a promising biomarker for various diseases. In this study, the expression of let-7b, miR-30c, and miR-200c was studied in breast cancer tissues to evaluate the potential relationship with known clinicopathological parameters.
METHODS
Quantitative real-time polymerase chain reaction was performed to determine the expression level of three miRNAs in 37 pairs of noncancerous normal and cancer tissues and an additional 38 cancer tissues from patients with invasive ductal carcinoma.
RESULTS
miR-200c expression was higher in cancer tissues compared to noncancerous normal tissues, and its ratio was correlated with patient age at surgery, type of surgery, and Ki-67 expression. The expression level of let-7b in cancer tissues was inversely correlated with lymph node metastasis, histological grade, and Ki-67 expression but positively correlated with estrogen and progesterone receptor expression. miR-200c expression level was positively correlated with Her-2 expression. The miR-30c expression level in breast cancer was not correlated with any parameters.
CONCLUSIONS
miR-200c and let-7b could be used as biomarkers in patients with breast cancer, but its pathological mechanism should be determined.
-
Citations
Citations to this article as recorded by  - Evaluating MicroRNAs as diagnostic tools for lymph node metastasis in breast cancer: Findings from a systematic review and meta-analysis
Coral González Martínez, Stavros Therapontos, Jose A. Lorente, Miriam Alcaide Lucena, F.Gabriel Ortega, M.Jose Serrano
Critical Reviews in Oncology/Hematology.2025; 207: 104598. CrossRef - High DRC Levels Are Associated with Let-7b Overexpression in Women with Breast Cancer
Jarline Encarnación, Carmen Ortiz, Ralphdy Vergne, Wanda Vargas, Domenico Coppola, Jaime Matta
International Journal of Molecular Sciences.2016; 17(6): 865. CrossRef
- Prognostic Significance of Methylation Profiles in Urothelial Carcinomas of the Bladder.
-
Hee Jung Park, Eui Jin Lee, Sang Yun Ha, Ghee Young Kwon, Young Lyun Oh, Kyoung Mee Kim, Dae Shick Kim, Seongil Seo, Hyun Moo Lee, Han Yong Choi
-
Korean J Pathol. 2010;44(6):623-630.
-
DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.6.623
-
-
3,507
View
-
21
Download
-
1
Crossref
-
Abstract
PDF
- BACKGROUND
Study on epigenetics of urothelial carcinomas has expanded and allowed better understanding of their correlation with clinicopathologic features. The aim of this study was to determine reliable predictive epigenetic markers for patients with urothelial carcinoma of urinary bladder.
METHODS
In 64 urothelial carcinomas of the urinary bladder, methylationspecific polymerase chain reaction with RAS association domain family 1A (RASSF1A), adenomatous polyposis coli (APC), death-associated protein-kinase (DAPK), runt-related transcription factor 3 (RUNX3), p14, p16 and MGMT was performed and correlated the results with p53 mutations, DNA ploidy, clinicopathologic parameters and recurrences.
RESULTS
Hypermethyation of RASSF1A, APC, DAPK, RUNX3, p14, p16 and MGMT promoters was observed in 35 (54.7%), 29 (45.3%), 18 (28.1%), 18 (28.1%), 9 (14.1%), 2 (3.1%), and 6 (9.4%) cases, respectively. Hypermethylation of RUNX3 and APC was significantly associated with high histologic grades and aneuploidy. Methylation of DAPK was significantly associated with muscle invasion. Methylation of DAPK and RUNX3 genes was significantly associated with recurrence. In survival analyses, methylation of RUNX3 gene and methylation-high (methylation at two or more loci) phenotype was significantly associated with poor recurrence-free survival.
CONCLUSIONS
Methylation of RUNX3 gene and methylation-high phenotype are significant indicator of recurrence.
-
Citations
Citations to this article as recorded by - DAPK Promoter Methylation and Bladder Cancer Risk: A Systematic Review and Meta-Analysis
Lihe Dai, Chong Ma, Zhensheng Zhang, Shuxiong Zeng, Anwei Liu, Shijie Tang, Qian Ren, Yinghao Sun, Chuanliang Xu, Shengtao Zhou
PLOS ONE.2016; 11(12): e0167228. CrossRef
- The Frequency of BRAF Mutation in Very Small Papillary Thyroid Carcinomas.
-
Taeeun Kim, Ji Hyun Roh, Hee Jung Park, Jee Eun Kwon, So Young Kang, Yoon La Choi, Young Lyun Oh
-
Korean J Pathol. 2010;44(3):308-314.
-
DOI: https://doi.org/10.4132/KoreanJPathol.2010.44.3.308
-
-
4,507
View
-
21
Download
-
3
Crossref
-
Abstract
PDF
- BACKGROUND
Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid and BRAF (V600E) is the most frequent genetic alteration in PTCs. The aim of this study was to investigate the frequency of BRAF mutation, especially in very small PTCs.
METHODS
We analyzed the presence of the BRAF mutation in PTCs in subgroups defined by tumor size (0.5 cm intervals).
RESULTS
Of 140 patients, 85 (60.7%) showed a BRAF mutation.
The frequency of BRAF mutation in the subgroup was: 45/70 (64.3%) in tumors less than 0.5 cm in size, 18/28 (64.3%) in 0.6-1 cm tumors, 10/22 (45.5%) in 1.1-1.5 cm tumors, and 12/20 (60.0%) in 1.6-2 cm tumors. There was no statistically significant association between BRAF mutation and tumor size (p = 0.44). Similarly, BRAF mutation was not statistically related to age, sex, stage, perithyroidal extension or lymph node metastasis. On multivariate logistic regression analysis, tumor sizes larger than 0.5 cm were associated with lymph node metastasis (odds ratio, 3.79; 95% confidence interval, 1.81 to 7.91; p < 0.01).
CONCLUSIONS
The BRAF mutation is not related to tumor size even in very small PTCs. The similar frequency of BRAF mutation in very small PTCs suggests that the BRAF mutation is a very early event in the tumorigenesis of PTCs.
-
Citations
Citations to this article as recorded by - BRAF mutation detection in indeterminate thyroid cytology specimens
N. Paul Ohori, Rashi Singhal, Marina N. Nikiforova, Linwah Yip, Karen E. Schoedel, Christopher Coyne, Kelly L. McCoy, Shane O. LeBeau, Steven P. Hodak, Sally E. Carty, Yuri E. Nikiforov
Cancer Cytopathology.2013; 121(4): 197. CrossRef - BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma
Dongbin Ahn, June Sik Park, Jin Ho Sohn, Jae Hyug Kim, Sun-Kyun Park, An Na Seo, Ji Young Park
Auris Nasus Larynx.2012; 39(2): 198. CrossRef - Mutational Patterns and Novel Mutations of the BRAF Gene in a Large Cohort of Korean Patients with Papillary Thyroid Carcinoma
Chan-Kwon Jung, So-Young Im, Yeo-Ju Kang, Hyoungnam Lee, Eun-Sun Jung, Chang-Suk Kang, Ja-Seong Bae, Yeong-Jin Choi
Thyroid.2012; 22(8): 791. CrossRef
|
E-submission
